2F9U

HCV NS3 protease domain with NS4a peptide and a ketoamide inhibitor with a P2 norborane

Summary for 2F9U

• Entry DOI: 10.2210/pdb2f9u/pdb
• Related: 1A1R 1JXP 1N1L 2A4G 2A4Q 2A4R
• Descriptor: NS3 protease/helicase', polyprotein, ZINC ION, ... (5 entities in total)
• Functional Keywords: hcv, hepatitis c protease, ns3 protease, ketoamide inhibitor, viral protein
• Biological source: Hepatitis C virus; More
• Total number of polymer chains: 4
• Total formula weight: 47861.86

Authors

Venkatraman, S.,Njoroge, F.G.,Wu, W.,Girijavallabhan, V.,Prongay, A.J.,Butkiewicz, N.,Pichardo, J. (deposition date: 2005-12-06, release date: 2006-06-06, Last modification date: 2024-11-20)

Primary citation

Venkatraman, S.,Njoroge, F.G.,Wu, W.,Girijavallabhan, V.,Prongay, A.J.,Butkiewicz, N.,Pichardo, J.
Novel Inhibitors of Hepatitis C NS3-NS4A Serine Protease Derived from 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid.
Bioorg.Med.Chem.Lett., 16:1628-1632, 2006

PubMed Abstract: Prolonged hepatitis C infection is the leading cause for cirrhosis of the liver and hepatocellular carcinoma. The etiological agent HCV virus codes a single polyprotein of approximately 3000 amino acids that is processed with the help of a serine protease NS3A to produce structural and non-structural proteins required for viral replication. Inhibition of NS3 protease can potentially be used to develop drugs for treatment of HCV infections. Herein, we report the development of a series of novel NS3 serine protease inhibitors derived from 2-aza-bicyclo[2.2.1]-heptane carboxylic acid with potential therapeutic use for treatment of HCV infections.

PubMed: 16413182
DOI: 10.1016/j.bmcl.2005.12.046

Experimental method

X-RAY DIFFRACTION (2.6 Å)